Malignant Endocrine Neoplasm — Trials

Malignant Endocrine Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

1,801 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 577
Recruiting: 291
Ph III recruiting: 33
Growth YoY: +2.2%
Industry share: 34%
Top sponsor: National Cancer Institute (NCI)
Termination share: 36.5%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (238)

clinicaltrialsPublishedShowing 1–3 of 3 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT04760288	A Study of Pralsetinib Versus Standard of Care (SOC) for Treatment of RET-Mutated Medullary Thyroid Cancer (MTC).(AcceleRET-MTC)	withdrawn	Phase 3	0	Hoffmann-La RocheINDUSTRY	1	Jan 5, 2024	clinicaltrials
NCT03334487	Study Evaluating the Safety of Rovalpituzumab Tesirine for Third-Line and Later Treatment of Subjects With Relapsed or Refractory Small Cell Lung Cancer	withdrawn	Phase 3	0	AbbVieINDUSTRY	7	Dec 26, 2018